ProQinase GMBH was established as a wholly owned subsidiary of the Tumor Biology Centre (TBC), Freiburg, in April 2001 to commercialize the centre's research on protein kinases. During their years of basic research at TBC, ProQinase's scientists have developed extensive know-how in the protein kinase arena and have established a range of tools and assays to identify, produce, manipulate and screen protein kinases' activities. These tools and assays now constitute the Integrated Technology Platform Protein Kinases that ProQinase is commercializing through a hybrid business model. The company will apply the platform technology to its own in-house drug discovery and development activities and also make it available to external clients on a fee-for-service basis.

Summarizing the month in European dealmaking.

Summarizing the month in European dealmaking.